| Name | (S,R,S)-AHPC hydrochloride |
| Description | (S,R,S)-AHPC hydrochloride (Protein degrader 1 hydrochloride) is a building block in the synthesis of proteolysis-targeting chimera technologies (PROTACs). |
| In vitro | Small molecule-induced protein degradation is an attractive strategy for the development of chemical probes.Protein degraders have the power to abrogate all of the functions of a drug target at once, including scaffolding functions which are difficult to target with small molecule inhibitors. A novel class of PROTACs that incorporate small molecule VHL ligands to successfully degrade HaloTag7 fusion proteins is developed. HaloPROTACs will inspire the development of future PROTACs with more drug-like properties. In HEK 293 cellsstably expressing GFP-HaloTag7,24 hour treatment with HaloPROTAC1 leads to less than 20% degradation, the longer HaloPROTAC2 leads to nearly 70% degradation of GFP-Halotag7 at 2.5 μM.HaloPROTACs containing protein degrader 1 leads to nearly 70% degradation of GFP-HaloTag7, when sufficiently long linkers are used |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 10 mM, Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (4.28 mM), Sonication is recommended.
|
| Keywords | VHL ligand-1 | VHL ligand1 | VHL Ligand 1 Hydrochloride | VHL ligand 1 | VH032-NH2 | ULM1 | ULM 1 | Protein degrader 1 Hydrochloride | Ligands for E3 Ligase | LigandforE3Ligase | Ligand for E3 Ligase | Inhibitor | inhibit | E3 ligase-recruiting Moiety | AHPC Hydrochloride | (S,R,S)AHPC hydrochloride | (S,R,S)-AHPC | (S,R,S) AHPC hydrochloride |
| Inhibitors Related | Lenalidomide-Br | PT-179 | (S)-Thalidomide | Thalidomide | (S,R,S)-AHPC | Pomalidomide | Amino-PEG1-C2-acid | Lenalidomide | Thalidomide-5-OH | 5-Aminothalidomide | Thalidomide 5-fluoride | Thalidomide-O-COOH |
United States
